Liraglutide (NN2211)

Catalog No.S8256 Synonyms: Victoza, Liraglutida, Liraglutidum

For research use only.

Liraglutide (Victoza, Liraglutida, Liraglutidum, NN2211) is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.

Liraglutide (NN2211) Chemical Structure

CAS No. 204656-20-2

Selleck's Liraglutide (NN2211) has been cited by 13 publications

Purity & Quality Control

Choose Selective Glucagon Receptor Inhibitors

Biological Activity

Description Liraglutide (Victoza, Liraglutida, Liraglutidum, NN2211) is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Targets
GLP-1 receptor [1]
In vitro

Liraglutide attenuates induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro and may afford protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease. In vitro studies demonstrates GLP-1R-dependent liraglutide-mediated inhibition of stimulated PAI-1 and VAM expression[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2 NWTwV4NxWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFjVVJAxNCBzLDCxNEwhOTByLDDhcoQhOTByMDDucY9tN0x? MYG0PEBp MXHJR|UxhjFyMDDuUS=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB6MUGwPEc,OzFyOEGxNFg9N2F-
MiaPaca-2 M4m5eGNmdGxidnnhZoltcXS7IHHzd4F6 MYGwMEAyOCxiMUCwMEAyODByIH7N NULNd4k1PDhiaB?= NVewWG5uXGinIHnubIljcXSxcomg[YZn\WO2czDvckBk\WyuII\pZYJqdGm2eTDhcoQh[2WubDDueY1j\XJid3Xy[UB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JI9vdHliYYSgeIhmKGOxbnPlcpRz[XSrb36gc4YhOSxyMECgco1wdC:OIH\vdkBtcXKjZ3z1eIll\Q>? NGLCT5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5O|k6QCd-Mkm4PVc6QTh:L3G+
H9c2 NF3BbGRHfW6ldHnvckBie3OjeR?= MkLONVAx6oDxbl2= NIr1S3cyKGh? M2HLWGxqemGpbIX0bYRmKHKndnXyd4VlKHSqZTDkc5dvemWpdXzheIlwdiCxZjDTTXJVOSCrbnT1Z4VlKGK7IGTOSk3PuSCjbnSgbJlxd3irYR?= NHTVWlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3NVc{Pid-Mkm1O|E4OzZ:L3G+
MC3T3-E1 MWPBdI9xfG:|aYOgZZN{[Xl? Mn3hNEwhOTBuIEGwNEwhd3JiMUCwNEBvVQ>? M2DGTFQ5KGh? M4W0PYxqemGpbIX0bYRmKHO3cIDy[ZN{\WRidHjlJIFxd3C2b4Ppd{Bw\iCPQ{PUN{1GOSClZXzsdy=> M13OVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[zNFY4Lz5{OUS2N|A3PzxxYU6=
MCF-7 MWrQdo9tcW[ncnH0bY9vKGG|c3H5 MXWxNEwhOTByLDCxMFAxOCCjbnSgNVAtODByIH7N M{TjdFQ5KGh? MkP3UIlz[WeudYTp[IUhcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[W6mIIDyc41wfGW|IHHwc5B1d3OrczDpckB1cGViTVPGMVch[nKnYYP0JINidmOncjDj[YxtKGyrbnW= MljMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl|OUO0OVkoRjJ7M{mzOFU6RC:jPh?=
SH-SY5Y MkK1SpVv[3Srb36gZZN{[Xl? M3K1SlExOOLCiX7N Mme2NVYhcA>? NF7oWIlNcXKjZ3z1eIll\SC{ZYPvcJZmeyCXUGKgbY4hfGinIH7leZJw[myjc4TvcYEhW0hvU2m1XUBk\WyuIHzpcoUv NWjNSY11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO|A1PTJpPkK5NVcxPDV{PD;hQi=>
HEK293 M3LXN2Z2dmO2aX;uJIF{e2G7 NXjoSVhKfXBidH:gN|AhdWmwcx?= MUTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFfMVFEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bp[XKkb4LpcochdUOncoXs[YFvKGGwZDDtR4l1emmwZTDmeZNm\CCHcHHjJJBzd3SnaX6gZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY1HNVEBt\X[nbDD1dEB1dyB|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygSWM2OCB;IECuNFAxODZ5IN88UU4> NUHmT4N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|E{PTVpPkK4O|cyOzV3PD;hQi=>
HEK293 M1XieGZ2dmO2aX;uJIF{e2G7 NG[1bHo{OCCvaX7z NHzEe25C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGdNWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGGodHXyJFMxKG2rboOgZpkhUFSURjDt[ZRpd2RuIFXDOVAhRSByLkCwO|Qh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlAyQDZ4Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot p-ERK / p-JNK / p-p38 / p-AKT / IκB-α 24217090
In vivo In vivo studies of vascular reactivity and immunohistochemical analysis are performed in the ApoE-/- mouse model. They demonstrate significant improvement in endothelial function in liraglutide treated mice, a GLP-1R dependent effect. Liraglutide treatment also increases endothelial nitric oxide synthase (eNOS) and reduces intercellular adhesion molecule-1 (ICAM-1) expression in aortic endothelium, an effect again dependent on the GLP-1R[3]. Liraglutide reduces hyperglycemia in T2D mouse models by increasing pancreatic b cell mass through enhanced proliferation[2].

Protocol (from reference)

Cell Research:

[3]

  • Cell lines: human umbilical vein endothelial cell line C11-STH20
  • Concentrations: 100 nM
  • Incubation Time: 16 h
  • Method:

    C11-STH cells are cultured to confluence at 37°C in gelatin-coated Nunclon cell culture dishes in Media-199 supplemented with penicillin/streptomycin, 20% FCS, 20 µg/ml endothelial cell growth factor and 20 µg/ml heparin. C11-STH cells are incubated under serum free conditions with liraglutide (100 nM) or the GLP-1 receptor antagonist exendin (9-39) (100 nM) alone or with 10 ng/ml TNFα for 16 h alone or in combination with liraglutide and/or exendin (9-39). ELISA assays for VCAM-1 and ICAM-1 are performed using conditioned medium from C11-STH cells to determine protein expression levels.

Animal Research:

[2]

  • Animal Models: Athymic nude mice
  • Dosages: 300 μg/kg/day
  • Administration: s.c.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 3751.25
Formula

C172H265N43O51

CAS No. 204656-20-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05419856 Not yet recruiting Drug: 4P-004|Drug: Placebo Knee Osteoarthritis 4Moving Biotech|4P-Pharma August 1 2022 Phase 1
NCT05467514 Recruiting Drug: Liraglutide Diabetes Mellitus Type 1 David Sanchez Garcia|Instituto Mexicano del Seguro Social July 2022 Phase 3
NCT05268237 Not yet recruiting Drug: Liraglutide|Drug: Placebo Diabete Type 2 Biolingus|Chinese University of Hong Kong March 2022 Phase 1|Phase 2
NCT04763564 Recruiting Drug: Liraglutide Pen Injector|Drug: Placebo Pen Injector Pouchitis|Irritable Pouch Syndrome University of North Carolina Chapel Hill|Novo Nordisk A/S March 22 2022 Phase 2
NCT04057261 Withdrawn Drug: Liraglutide Pen Injector [Victoza]|Drug: Placebo Type 2 Diabetes|Cardiovascular Diseases RWTH Aachen University|Novo Nordisk A/S November 2020 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to know whether S8256 Liraglutide is free base or salt form?

Answer:
Our S8256 Liraglutide is a TFA salt.

Tags: buy Liraglutide (NN2211) | Liraglutide (NN2211) supplier | purchase Liraglutide (NN2211) | Liraglutide (NN2211) cost | Liraglutide (NN2211) manufacturer | order Liraglutide (NN2211) | Liraglutide (NN2211) distributor